Citius Oncology Inc (CTOR) Stock Price, Quote & News

Company Profile

Citius Oncology, Inc. focuses on the development and commercialization of innovative targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. is a subsidiary of Leonard-Meron Biosciences, Inc.

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 908 967 6677

Address:

11 Commerce Drive, First Floor, Cranford, United States

HypnoTrader Apr. 3 at 8:06 AM

$CTOR correct spelling is "crap". You are welcome.

0 · Reply

SagaSeeker Apr. 3 at 12:44 AM

$CTOR Bull trap

0 · Reply

NYC100 Apr. 2 at 5:35 PM

$CTOR for you 😂😂

0 · Reply

SKEETER_1 Apr. 2 at 4:55 PM

$CTOR trap

1 · Reply

jayhip Apr. 2 at 3:54 PM

$CTOR

0 · Reply

BestNwest Apr. 1 at 5:24 AM

$CTOR

0 · Reply

focafoca99 Apr. 1 at 1:15 AM

$CTOR published a commercial update on the U.S. launch of LYMPHIR.

0 · Reply

SKEETER_1 Mar. 31 at 11:38 PM

$CTOR if you didnt sell today your stuck as the paid pump all exited today

0 · Reply

SKEETER_1 Mar. 31 at 11:36 PM

$CTOR everything in PR is a sales floor pitch verbal hand job for its next batch of suckers. Investors have lost 99% and all they get is the same wording hes been using for the last 5 years. Hopeful, encouraged, sequential, ingaged, expand, strong demand, uptake. Execute, penetrate. Every PR is perfectly worded that sounds great but you cant sue them if you took the words the wrong way. Its on you if you take this report as positive news. If the numbers were actually good they would share them with you.

0 · Reply

NYC100 Mar. 31 at 9:59 PM

$CTOR you wish 😂😂

0 · Reply

Citius Oncology Provides Commercial Update on LYMPHIR™ Launch Highlighting Early Adoption and Expanding Clinical Development

CTXR

Mar 24, 2026, 8:00 AM EDT - 15 days ago

Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR™ in Discussions with Leading Cutaneous Lymphoma Experts

CTXR

$Citius Oncology Announces Positive Topline Results from Investigator‑Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers$

Mar 10, 2026, 8:47 AM EDT - 4 weeks ago

Citius Oncology Announces Positive Topline Results from Investigator‑Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers

CTXR

Mar 4, 2026, 9:15 AM EST - 5 weeks ago

Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR™ (E7777) Dosing Prior to Commercial CAR‑T Therapy in High‑Risk Diffuse Large B‑Cell Lymphoma

CTXR

Feb 13, 2026, 8:00 AM EST - 7 weeks ago

Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™

CTXR

Feb 13, 2026, 8:00 AM EST - 7 weeks ago

Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™

CTXR

Feb 11, 2026, 8:00 AM EST - 2 months ago

Citius Oncology Expands International Distribution of LYMPHIR™ to European Union Through Exclusive Agreement with Uniphar

CTXR

Dec 23, 2025, 4:30 PM EST - 3 months ago

Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update

CTXR

Dec 23, 2025, 4:30 PM EST - 3 months ago

Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update

CTXR

Dec 10, 2025, 4:30 PM EST - 4 months ago

Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules

CTXR

Dec 9, 2025, 8:30 AM EST - 4 months ago

Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules

CTXR

Dec 4, 2025, 8:37 AM EST - 4 months ago

Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim

CTXR

Dec 1, 2025, 12:00 PM EST - 4 months ago

Citius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL)

CTXR

Nov 25, 2025, 8:00 AM EST - 4 months ago

Citius Oncology to Exhibit at the 67th American Society of Hematology (ASH) Annual Meeting

CTXR

Nov 21, 2025, 8:37 AM EST - 4 months ago

Citius Oncology to Advance Commercial Launch of LYMPHIR™ with Verix AI Integration

CTXR

Oct 20, 2025, 8:37 AM EDT - 6 months ago

Citius Oncology Signs U.S. Distribution Agreement with McKesson to Support LYMPHIR™ Commercial Launch

Oct 17, 2025, 5:00 PM EDT - 6 months ago

Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences

CTXR

Oct 16, 2025, 8:47 AM EDT - 6 months ago

Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR™

CTXR

Oct 7, 2025, 8:47 AM EDT - 6 months ago

Citius Oncology Establishes International Access to LYMPHIR™ via Named Patient Programs in Southern Europe

Sep 10, 2025, 4:30 PM EDT - 7 months ago

Citius Oncology Announces Closing of $9.0 Million Registered Direct Offering and Concurrent Private Placement

CTXR

Sep 9, 2025, 8:30 AM EDT - 7 months ago

Citius Oncology Announces Pricing of $9.0 Million Registered Direct Offering and Concurrent Private Placement

CTXR

Aug 22, 2025, 8:47 AM EDT - 8 months ago

Citius Oncology Deploys AI Platform to Amplify the Performance of its Commercial Team Ahead of LYMPHIR Launch

CTXR

Aug 12, 2025, 4:30 PM EDT - 8 months ago

Citius Oncology, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update

Jul 17, 2025, 4:30 PM EDT - 9 months ago

Citius Oncology Announces Closing of $9.0 Million Public Offering

CTXR

Jul 16, 2025, 9:15 AM EDT - 9 months ago

Citius Oncology Announces Pricing of $9.0 Million Public Offering

CTXR

Jul 15, 2025, 8:32 AM EDT - 9 months ago

Citius Oncology Expands Distribution Network for LYMPHIR with Execution of Distribution Services Agreement with Cencora

CTXR

Jun 17, 2025, 8:08 AM EDT - 10 months ago

Citius Oncology Anticipates Commercial Launch of LYMPHIR™ in 2025

CTXR

May 14, 2025, 4:30 PM EDT - 11 months ago

Citius Oncology, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update

May 5, 2025, 8:37 AM EDT - 1 year ago

Citius Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

CTXR

Feb 14, 2025, 4:30 PM EST - 1 year ago

Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update

CTXR

Feb 14, 2025, 4:30 PM EST - 1 year ago

Citius Oncology, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update

Feb 6, 2025, 8:55 AM EST - 1 year ago

Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services

CTXR

Jan 7, 2025, 8:08 AM EST - 1 year ago

Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025

CTXR

Jan 6, 2025, 7:50 AM EST - 1 year ago

Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives

CTXR

Dec 27, 2024, 5:00 PM EST - 1 year ago

Citius Oncology, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update

HypnoTrader Apr. 3 at 8:06 AM

$CTOR correct spelling is "crap". You are welcome.

0 · Reply

SagaSeeker Apr. 3 at 12:44 AM

$CTOR Bull trap

0 · Reply

NYC100 Apr. 2 at 5:35 PM

$CTOR for you 😂😂

0 · Reply

SKEETER_1 Apr. 2 at 4:55 PM

$CTOR trap

1 · Reply

jayhip Apr. 2 at 3:54 PM

$CTOR

0 · Reply

BestNwest Apr. 1 at 5:24 AM

$CTOR

0 · Reply

focafoca99 Apr. 1 at 1:15 AM

$CTOR published a commercial update on the U.S. launch of LYMPHIR.

0 · Reply

SKEETER_1 Mar. 31 at 11:38 PM

$CTOR if you didnt sell today your stuck as the paid pump all exited today

0 · Reply

SKEETER_1 Mar. 31 at 11:36 PM

0 · Reply

NYC100 Mar. 31 at 9:59 PM

$CTOR you wish 😂😂

0 · Reply

SKEETER_1 Mar. 31 at 8:00 PM

$CTOR

0 · Reply

jayhip Mar. 31 at 7:00 PM

$CTOR woah

0 · Reply

TwongStocks Mar. 31 at 1:27 PM

$CTOR PR this morning. $CTXR Marketing campaign https://bullseyealerts.com/ctxr-14/

0 · Reply

TwongStocks Mar. 31 at 1:21 PM

$CTOR $CTXR No forward guidance or unaudited sales numbers in the PR. But they state that the Lymphir launch is progressing well. Next ER is due by May 15 (45 days after Mar 31). So we will know by mid-May how the Jan-Mar sales went.

1 · Reply

TwongStocks Mar. 31 at 1:12 PM

$CTOR $CTXR Citius Oncology Provides Commercial Update on LYMPHIR™ Launch Highlighting Early Adoption and Expanding Clinical Development https://www.prnewswire.com/news-releases/citius-oncology-provides-commercial-update-on-lymphir-launch-highlighting-early-adoption-and-expanding-clinical-development-302729879.html

0 · Reply

Stock_Catcher Mar. 31 at 1:11 PM

$CTOR Citius Oncology Provides Commercial Update on LYMPHIR™ Launch Highlighting Early Adoption and Expanding Clinical Development

0 · Reply

SweStonk Mar. 26 at 8:46 PM

$CTOR I knew this was gonna drop but never thought it would be this low this fast. Wonder how many got stuck after $6 run. They would need a miracle only to get back to ~$2 Even more for $6. Guess distribution to $CTXR shareholders wont happen for atleast 4+ years if ever. Not possible for distribution when company risk R/S and if they do a R/S the distribution could trigger another R/S so that would prevent a distribution to happen at all.

1 · Reply

SweStonk Mar. 26 at 3:55 PM

$CTOR Bloodbath continue! 0.1 incoming? 🥲

0 · Reply

SKEETER_1 Mar. 25 at 4:55 PM

$CTOR somebody at Armistice is getting fired. The only institution that had a significant postion in CTOR is dumping shares at heavy loss.

0 · Reply

SweStonk Mar. 24 at 9:31 PM

$CTOR Looking at your older posts on different tickers it seem you put bullish stamp when shit is about to go even lower. ~30% drop to be exact.

2 · Reply

BestNwest Mar. 24 at 3:51 PM

$CTOR watch this in few days or

1 · Reply

TwongStocks Mar. 24 at 12:01 PM

$CTOR Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR™ in Discussions with Leading Cutaneous Lymphoma Experts https://www.prnewswire.com/news-releases/citius-oncology-to-participate-in-usclc-annual-workshop-2026-highlighting-lymphir-in-discussions-with-leading-cutaneous-lymphoma-experts-302723119.html

0 · Reply

Market Cap	60.65M
Revenue (ttm)	0.00
Net Income (ttm)	-24.76M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.26

Volume	271,600
Avg Vol	287,584
Day's Range	N/A - N/A
Shares Out	88.28M
Stochastic %K	51%
Beta	3.42
Analysts	Strong Sell
Price Target	$6.00